Ozempic for Diabetes vs Wegovy for Weight Loss: What's the Actual Difference?

The confusion is understandable. Ozempic and Wegovy are both weekly injections. Both are made by Novo Nordisk. Both contain semaglutide. Type the active ingredient into a search engine and you get results for both products interchangeably.

But they are not the same product, and the differences between them — dose, licensed indication, NHS availability, cost, and prescribing pathway — have significant practical consequences for anyone trying to access treatment in the UK.

This article explains exactly what separates them, and what that means for you.

The Same Molecule, Different Jobs

Semaglutide is a GLP-1 receptor agonist. It mimics the action of glucagon-like peptide-1, a gut hormone that promotes satiety, slows gastric emptying, and acts on appetite centres in the brain. It also stimulates insulin secretion and suppresses glucagon in a glucose-dependent manner, which is why it was originally developed for type 2 diabetes.

Ozempic (semaglutide 0.5mg and 1mg) was approved for type 2 diabetes management. Wegovy (semaglutide 2.4mg) was then developed at a higher dose specifically for chronic weight management. Same molecule, different doses, different regulatory approvals, different clinical purposes.

The dose difference is not trivial. The additional weight loss from 2.4mg compared to 1mg is meaningful — and it reflects the fact that the appetite-suppressing effects of semaglutide are dose-dependent.

What Ozempic Is Licensed For

Ozempic holds a MHRA licence for the treatment of type 2 diabetes in adults, as an adjunct to diet and exercise, when metformin is not appropriate or has been insufficient. It comes in two dose strengths: 0.5mg and 1mg, administered as a weekly subcutaneous injection.

In 2021, a 2mg dose of Ozempic was also approved, specifically for people with type 2 diabetes who have inadequate glycaemic control on lower doses. This higher Ozempic dose is distinct from the Wegovy dose progression.

Ozempic also carries a secondary benefit in its label: cardiovascular risk reduction. The SUSTAIN-6 trial showed a significant reduction in MACE (major adverse cardiovascular events) in people with type 2 diabetes and high cardiovascular risk. This cardiovascular benefit is part of why Ozempic has become a cornerstone of type 2 diabetes management.

What Wegovy Is Licensed For

Wegovy holds a MHRA licence for chronic weight management in adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea), as an adjunct to a reduced-calorie diet and increased physical activity.

The STEP 1 trial (semaglutide 2.4mg vs placebo, n=1961) reported 14.9% mean body weight reduction over 68 weeks.

The licensing distinction matters for prescribing in the UK: a prescriber writing Wegovy for weight loss is prescribing within the licensed indication. A prescriber writing Ozempic for weight loss — in a patient who does not have type 2 diabetes — is prescribing off-label. Both can be done legally by a qualified prescriber, but they carry different governance implications.

Why Ozempic Became the Weight Loss Drug People Talk About

Ozempic was approved for diabetes before Wegovy reached the market. When its weight loss effects became widely known, high demand from people seeking it for weight management caused significant supply problems for people with type 2 diabetes who depended on it.

This is still an active problem in some regions. NHS prescribing guidelines now explicitly advise prescribers not to initiate Ozempic for weight management in patients without type 2 diabetes. The appropriate licensed product for weight management is Wegovy.

The Dose Difference in Practice

This is the crux of it. Ozempic doses top out at 1mg (or 2mg for diabetes management). Wegovy's maintenance dose is 2.4mg, with the newly approved 7.2mg dose now available in the UK for partial responders.

The dose-response relationship for weight loss with semaglutide is well established. Higher doses produce greater appetite suppression and greater weight loss. Using Ozempic at 1mg for weight loss is not the same as using Wegovy at 2.4mg — you are getting less of the drug, which translates to meaningfully less weight loss in most patients.

This is not a minor distinction. For context:

• Semaglutide 0.5mg (low Ozempic dose): approximately 3-4% body weight reduction in people without diabetes
• Semaglutide 1mg (Ozempic maintenance dose): approximately 5-6% body weight reduction
• Semaglutide 2.4mg (Wegovy maintenance dose): 14.9% in STEP 1

For a detailed comparison of how Wegovy stacks up against Mounjaro at different doses, see /guides/mounjaro-vs-wegovy-uk-2026.

Ozempic vs Wegovy: The Key Differences

NHS Prescribing: Who Gets What

This is where the divergence has real-world impact.

Ozempic on the NHS: Available for type 2 diabetes patients where glycaemic control is insufficient on metformin or where metformin is contraindicated. Prescribed by GPs via standard NHS pathways. The diabetes indication is well-established and formulary-included across most ICBs.

Wegovy on the NHS: Available through specialist NHS weight management services, following NICE guidance TA875 (published 2023). The criteria are strict: BMI 35+ with at least one weight-related comorbidity, referred through a specialist weight management programme, and in most ICBs, the service must be commissioned. Not available via routine GP prescription.

In practice, accessing Wegovy on the NHS requires referral into a specialist service that is not yet universally commissioned. Many ICBs have waitlists of 12-24 months. Some have not yet commissioned the service at all.

For a detailed breakdown of NHS eligibility criteria, see /guides/nhs-glp1-eligibility-uk.

Private Prescribing Pathways

For patients who do not have type 2 diabetes and cannot access NHS specialist services, private prescribing is the current reality.

Private prescribers in the UK can prescribe Wegovy (on-label) for eligible patients with BMI 30+ and a weight-related comorbidity, or BMI 35+ without comorbidities in most cases. This follows the licensed indication and is the cleanest prescribing pathway.

Private prescribers can also prescribe Ozempic off-label for weight management in patients without diabetes, though this is increasingly unusual — Wegovy at the appropriate dose is the licensed option and should be preferred where available.

The cost difference is meaningful: Wegovy at 2.4mg runs to £150-220 per month privately, while Ozempic at 1mg is cheaper but delivers less benefit. Paying for the lower-dose product to save money is rarely good value when the clinical outcome is significantly less weight loss.

For a comparison of UK prescribing services by cost and quality, see /guides/best-glp1-prescriber-uk-2026.

The Cardiovascular Data: SELECT vs SUSTAIN-6

Both products have cardiovascular outcomes trial data, but the populations differ.

Ozempic's cardiovascular data comes from SUSTAIN-6, which studied semaglutide in people with type 2 diabetes and high cardiovascular risk. It showed a 26% relative reduction in MACE.

Wegovy's cardiovascular data comes from the SELECT trial, which studied semaglutide 2.4mg in people with established cardiovascular disease but without diabetes. It showed a 20% relative reduction in MACE. This is significant because it established cardiovascular benefit independent of diabetes or glycaemic effects — the benefit in SELECT was not mediated by glucose control.

The SELECT trial result was the basis for Wegovy's expanded indication in the UK covering cardiovascular risk reduction in patients with obesity. This is a distinct label benefit that Ozempic at diabetes doses does not carry for non-diabetic patients.

What About People Who Have Both Conditions?

A common situation: a patient has type 2 diabetes and significant obesity. They are already on Ozempic for diabetes control. Should they switch to Wegovy?

This is a clinical conversation that needs to happen with a prescriber, but the general framework is:

• If glycaemic control is adequate on Ozempic and the primary remaining goal is additional weight loss, escalating to Wegovy 2.4mg (or the newly approved 7.2mg) may be appropriate
• If the patient is already on Ozempic 2mg (the high-dose diabetes version) and weight loss is still inadequate, their prescriber may consider whether Wegovy 2.4mg offers meaningful additional benefit, or whether a different medication class (such as Mounjaro/tirzepatide) would be a better step
• NHS prescribers are generally not permitted to prescribe Wegovy for weight management in a patient already receiving Ozempic for diabetes on the NHS — these are separate pathways with separate funding

The Mounjaro Question

No comparison of GLP-1 options in the UK is complete without mentioning tirzepatide (Mounjaro). Where semaglutide is a single GLP-1 receptor agonist, tirzepatide acts on both GLP-1 and GIP receptors.

The SURMOUNT-1 trial showed tirzepatide 15mg producing 20.9% weight loss at 72 weeks. The SURMOUNT-5 head-to-head trial (NEJM 2025) compared Mounjaro directly against standard Wegovy 2.4mg: Mounjaro 20.2% vs Wegovy 13.7%.

That comparison changes somewhat with the new Wegovy 7.2mg dose, which produced 20.7% weight loss in the STEP UP trial. At maximum approved doses, the two products are now closely matched on weight loss outcomes, with the cardiovascular data advantage currently sitting with Wegovy.

For a full comparison, see /guides/mounjaro-vs-wegovy-uk-2026.

Practical Summary

The confusion between Ozempic and Wegovy is mostly a product of marketing, media coverage, and the fact that both products entered public awareness simultaneously. Clinically, they serve different primary purposes, carry different doses, and are accessed through different pathways.

If you have type 2 diabetes: Ozempic is the licensed, NHS-available, first-line GLP-1 option.

If your goal is weight management without diabetes: Wegovy is the licensed product. Using Ozempic for weight management is off-label, delivers a lower dose, and produces less weight loss than the product specifically developed for that purpose.

If you are assessing private options: the cost difference between Ozempic and Wegovy should be weighed against the dose difference. Paying for Ozempic to save money while expecting Wegovy-level results is not a realistic expectation.

For guidance on which pathway best fits your circumstances, see /guides/nhs-glp1-eligibility-uk for NHS routes, and /guides/best-glp1-prescriber-uk-2026 for private options.